Cite
HARVARD Citation
Fischer, S. et al. (n.d.). P607 Clinical outcomes and immunogenicity analysis over 6 months following a switch from originator infliximab (Remicade®) to the biosimilar SB2 (Flixabi®) in inflammatory bowel disease patients. Journal of Crohn's and colitis. p. S416. [Online].